- Health Canada has approved Nduvra (tapinarof cream), 1%, available for topical treatment of moderate to severe atopic dermatitis in adults and pediatric patients aged ≥2 years, which is now available.
- Nduvra is a topical aryl hydrocarbon receptor agonist and offers a non-steroidal treatment option that can be prescribed by family physicians without specialist referral.
- The approval builds on tapinarof’s Canadian research history, with the drug discovered in Canada and clinical development involving participants from Canadian study sites.
- This marks tapinarof’s second approved indication in Canada, following its 2025 approval for plaque psoriasis in adults, expanding treatment options for people living with atopic dermatitis.
Takeaways:
The approval of Nduvra (tapinarof) 1% for moderate to severe atopic dermatitis gives Organon a first‑in‑class, steroid‑free topical that can be prescribed by family physicians without specialist referral, broadening access in Canada’s ~US$1.5B (2030) atopic dermatitis drug market and positioning it against topical calcineurin inhibitors, PDE4 and topical JAK inhibitors. With a second Canadian indication after plaque psoriasis (2025), the launch strengthens Organon’s dermatology portfolio and leverages a global AD therapeutics market growing ~8–9% CAGR, supporting mid‑term revenue diversification beyond women’s health.
Source: CA Newswire
